New drug targets and small molecules for promoting cardiac regeneration
Description of the granted funding
Currently, there is no effective drug treatment for post-infarction heart failure, which is a major public health issue and a huge economic burden. The adult human heart cannot repair the tissue injury caused by myocardial infarction, and the loss of cardiomyocytes leads to the development of heart failure. Remarkably, zebrafish and neonatal rodents can regenerate their hearts. This involves generation of new blood vessels and proliferation of existing cardiomyocytes, but the mechanisms regulating these phenomena are not fully understood. By elucidating endogenous mechanisms of cardiac regeneration, this work aims to identify new drug targets for cardiac regeneration-inducing therapies and develop small molecule compounds with potential cardiac regeneration-enhancing activity.
Show moreStarting year
2019
End year
2024
Granted funding
Related funding decisions
353109
Research costs of Academy Research Fellows(2022)
200 000 €
328909
Research costs of Academy Research Fellows(2019)
300 000 €
Funder
Research Council of Finland
Funding instrument
Academy research fellows
Other information
Funding decision number
321564
Fields of science
Pharmacy
Research fields
Farmasia
Identified topics
cardiovascular diseases